Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority Trial Comparing Short-Course Versus Standard-Course Antibiotic Therapy After ERCP With Early Intravenous-to-oral Switch in Patients With Acute Cholangitis (DATES-AC)

11 novembre 2026 mis à jour par: Seoul National University Hospital

Acute cholangitis is an infection of the bile ducts, usually caused by a blockage that prevents bile from flowing normally. It can lead to serious complications if not treated promptly. Treatment generally includes antibiotics and drainage of the blocked bile duct, usually through a procedure called endoscopic retrograde cholangiopancreatography (ERCP).

Although antibiotics are essential for treating acute cholangitis, the optimal duration of antibiotic treatment after successful bile duct drainage remains uncertain. Current guidelines generally recommend 4 to 7 days of antibiotic treatment. However, shorter treatment may be sufficient after the source of infection has been effectively controlled, potentially reducing unnecessary antibiotic exposure, side effects, hospital stay, and healthcare costs.

The purpose of this study is to determine whether a shorter course of antibiotic treatment (4 days) is as effective as the standard course (7 days) in patients with moderate to severe acute cholangitis who have undergone successful bile duct drainage.

This is a multicenter, randomized, open-label study involving adults aged 19 years or older with moderate to severe acute cholangitis. Patients whose bile duct obstruction has been successfully relieved by ERCP within one day of hospital admission and who meet the study eligibility criteria may participate. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups.

The short-course group will receive antibiotics for a total of 4 days, while the standard-course group will receive antibiotics for a total of 7 days. In both groups, intravenous antibiotics will initially be given for at least 2 days. Patients who are clinically stable and able to take oral medication will be switched to oral antibiotics as early as possible. Antibiotic selection may be adjusted according to bacterial culture results and antibiotic susceptibility testing. If the initial antibiotics are found to be ineffective, or if the patient's clinical condition requires additional treatment, the antibiotics may be changed or extended to ensure patient safety.

The primary outcome is the clinical cure rate within 14 days after randomization. Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Secondary outcomes include recurrence of cholangitis between days 14 and 30 among patients who initially achieve clinical cure, all-cause mortality within 30 days, total duration of antibiotic use, and patient-reported health status and satisfaction with treatment. The incidence of adverse events within 14 days will also be evaluated. Additional assessments will compare hospital stay and total treatment costs between the two groups.

Participants will be followed up at approximately 14 and 30 days after randomization to assess treatment outcomes, recurrence of infection, additional antibiotic use, and safety.

This study aims to provide evidence on whether a 4-day antibiotic treatment strategy, combined with early conversion from intravenous to oral antibiotics after successful bile duct drainage, can achieve comparable treatment outcomes to the standard 7-day regimen. The findings may help establish a more appropriate antibiotic treatment strategy for patients with acute cholangitis while reducing unnecessary antibiotic exposure and its associated burden.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

  • 1. Empirical IV Antibiotics Ceftriaxone + Metronidazole
  • 2. Culture-directed IV Antibiotics Ciprofloxacin Piperacillin/Tazobactam Ertapenem Meropenem
  • 3. PO Antibiotics Cefpodoxime proxetil Amoxicillin/Clavulanate

Type d'étude

Interventionnel

Inscription (Estimé)

330

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Jaihwan Kim, MD. PhD.
  • Numéro de téléphone: +82-31-787-7075
  • E-mail: drjaihwan@snu.ac.kr

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Gyeonggi-do
      • Ansan, Gyeonggi-do, Corée du Sud, 15355
        • Korea University Ansan Hospital
        • Contact:
      • Seongnam-si, Gyeonggi-do, Corée du Sud, 13620
        • Seoul National University Bundang Hospital
        • Contact:
    • Seoul
      • Seoul, Seoul, Corée du Sud, 03080
        • Seoul National University Hospital
        • Contact:
      • Seoul, Seoul, Corée du Sud, 07061
        • Seoul Metropolitan Government Seoul National University Boramae Medical Center
        • Contact:
      • Seoul, Seoul, Corée du Sud, 04763

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

19 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 19 years or older.
  • Patients who voluntarily agree to participate in the study and provide written informed consent after receiving a full explanation of the study.
  • Patients who meet the diagnostic criteria for suspected or definite acute cholangitis according to the Tokyo Guidelines 2018 (TG18), regardless of whether the underlying cause is benign or malignant.
  • Patients with moderate or severe acute cholangitis according to the TG18 severity grading criteria.
  • Patients who have undergone successful biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) within one calendar day of hospital admission, resulting in relief of biliary obstruction.

Exclusion Criteria:

  • Circulatory failure requiring vasopressor support at the time of ERCP.

  • Persistent or newly developed hypothermia (body temperature below 35°C) between hospital admission and screening.

  • Patients requiring intensive care unit (ICU) treatment.

  • Use of antibiotics within 7 days before hospital admission.

  • Use of systemic antibiotics for 7 days or longer within 90 days before study enrollment for an infection unrelated to the current episode of acute cholangitis.

  • History of recurrent acute cholangitis within the previous 3 months.

  • Complex biliary strictures classified as Bismuth type II or higher.

  • Biliary obstruction of unknown cause.

  • Acute cholangitis caused by dysfunction of a distal biliary stent when the stent was inserted less than 30 days before study enrollment.

  • Complications associated with acute cholangitis present at the time of study enrollment, including acute cholecystitis, acute pancreatitis, liver abscess, or intra-abdominal abscess.

  • Presence of an infection other than acute cholangitis at the time of study enrollment.

  • Patients at high risk of infective endocarditis caused by Gram-positive bacteria, including those with prosthetic heart valves, congenital heart disease, or a previous history of infective endocarditis.

  • Complications following ERCP, including perforation, bleeding, severe post-ERCP pancreatitis, or cardiopulmonary complications related to sedation.

  • Altered upper gastrointestinal anatomy due to previous upper abdominal surgery, except for Billroth I gastrectomy.

  • Immunocompromised patients, including:

    1. Patients receiving systemic corticosteroids at a dose equivalent to prednisolone 20 mg/day or higher for at least 14 consecutive days.
    2. Patients who have received cytotoxic chemotherapy, biological agents, or immunosuppressive therapy within the previous 3 months.
    3. Patients with hematologic malignancies or a history of hematopoietic stem cell transplantation.
    4. Patients who have undergone solid organ transplantation (liver, kidney, heart, lung, etc.) and are currently receiving immunosuppressive therapy.
    5. Patients with congenital or primary immunodeficiency disorders.
    6. Patients with advanced HIV infection, defined as a CD4-positive T-cell count below 200 cells/μL.
  • Pregnant or breastfeeding women.

  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: a shorter course of antibiotic treatment

4 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

Comparateur actif: a standard course of antibiotic treatment

7 days of antibiotics including PO antibioitcs

Comparision of duration of antibiotics

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
the clinical cure rate within 14 days after randomization
Délai: Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.

Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Recurrence rate of acute cholangitis
Délai: From Day 14 to Day 30 after randomization

Recurrence of cholangitis after cure

From Day 14 to Day 30 after randomization
All-cause mortality
Délai: Within 30 days after randomization

Death regardless of cause

Within 30 days after randomization
Patient-reported health status (EQ-5D-5L)
Délai: Day 2 and Day 14 after randomization

Patient self reports regarding health status

Day 2 and Day 14 after randomization
Patient satisfaction with treatment (TSQM-II)
Délai: Day 14 after randomization

Patient self reports regarding satisfaction with treatment

Day 14 after randomization
Total duration of antibiotic use
Délai: Within 30 days after randomization

Days with antibiotics

Within 30 days after randomization
DOOR/RADAR composite outcome
Délai: Day 30 after randomization

Scoring system regarding the treatment outcomes

Day 30 after randomization

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Hospital stays
Délai: Within 30 days after randomization

Duration of hospital stay

Within 30 days after randomization
Total medical costs
Délai: Within 30 days after randomization

Total medical costs for the treatment

Within 30 days after randomization

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Jaihwan Kim, Seoul National University Bundang Hospital

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

31 décembre 2029

Achèvement de l'étude (Estimé)

31 décembre 2029

Dates d'inscription aux études

Première soumission

11 novembre 2026

Première soumission répondant aux critères de contrôle qualité

11 novembre 2026

Première publication (Réel)

17 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • SNUBH-IMGPB-2026-01

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner